Management | Harnessing the Power of p53 to treat Cancer (2024)

David H. Mack, Ph.D.

Co-Founder, President & CEO

Prior to co-founding PMV Pharma with biologists Arnold Levine and Thomas Shenk, Dr. Mack was a general partner at Alta Partners from 2002 to 2013. His first investment was Angiosyn (acquired by Pfizer in 2005) where he was a Director and CEO. Prior to Alta, Dr. Mack co-founded and served as Vice President of Genomics Research at Eos Biotechnology (acquired by Protein Design Labs in 2003).

From 1994 to 1997, he served at Affymetrix as Head of Cancer Biology where he oversaw the development and application of DNA array technology in the areas of oncology and inflammation. Dr. Mack was also a pivotal member of the Polymerase Chain Reaction (PCR) Invention Group at Cetus (now Novartis) in the mid 1980s. Dr. Mack has co-authored more than 30 scientific articles and reviews, including papers published in Cell, Science, and Nature, and is an inventor on 26 issued US patents. Dr. Mack was an American Cancer Society Postdoctoral Fellow in microbiology and immunology at Stanford University School of Medicine. He received his Ph.D. from the University of Chicago, where he was a Howard Hughes Fellow in Molecular Genetics and Cell Biology, and a B.A. in Molecular Biology from the University of California, Berkeley.

Deepika Jalota, Pharm.D.

Chief Development Officer

Dr. Jalota has over 25 years of experience in the life sciences industry with a focus in oncology. Since joining PMV Pharma in 2019, Dr. Jalota has taken on progressively greater responsibilities and now serves as the Chief Development Officer. Prior to joining PMV Pharma, Dr. Jalota was Vice President, Head of Global Regulatory Strategy, Oncology I at Bayer HealthCare Pharmaceuticals where she was responsible for overseeing the development of global regulatory strategies for several early and late stage oncology projects, including Xofigo®, VITRAKVI® and Erleada®. From 2014-2016 at Bayer, she was responsible for overseeing the development of global regulatory strategies in Ophthalmology and Dermatology, including Eylea®.

Prior to working at Bayer for 12 years, Dr. Jalota was employed with Sanofi-Aventis, Forest Laboratories and Procter and Gamble Pharmaceuticals within various roles across drug development.

Dr. Jalota received her Pharm.D. from University of Florida, College of Pharmacy, and her B.S. in Pharmacy from Rutgers University, Ernest Mario School of Pharmacy.

Michael Carulli

Chief Financial Officer

Prior to joining PMV Pharma, Mr. Carulli was an Executive Director of R&D Financial Planning and Analysis at Celgene (now Bristol Myers Squibb) where he oversaw the financial and operational plans for the entire Research and Development organization. Over 10 years at Celgene he held multiple positions with increasing responsibility working closely on the R&D strategy, long range planning, and financial partnering to the Business Development and Alliance Management team. Mr. Carulli was the Chief of Staff to the President of Research & Early Development for 2 years, as well as the R&D finance lead for the Bristol Myers Squibb integration and Otezla divestiture to Amgen.

Combined, Mr. Carulli has over 20 years of financial management experience and has led many process improvement initiatives and implemented several business intelligence technology solutions. He received his MBA from Fordham University.

Marc Fellous, M.D.

Senior Vice President, Head of Clinical Development and Medical Affairs

Dr. Fellous joined PMV Pharma in April 2022 as Vice President, Clinical Development and Medical Affairs. Prior to joining PMV Pharma, he was Global Medical Affairs Head on larotrectinib, the first tumor-agnostic drug approved in the U.S. and Europe, and selitrectinib programs at Bayer. He held increasing leadership roles at Bayer and Roche for more than 13 years, contributing to the strategy and launch of multiple successful oncology products. Dr. Fellous completed his doctorate in general medicine at the University Paris V along with a specialized master’s degree in medical management from ESCP-Europe Business School.

Tim Smith

Senior Vice President, Head of Corporate Development & Investor Relations

Prior to joining PMV Pharma, Mr. Smith was Chief Business Officer of Verseau Therapeutics. He has held senior business development leadership roles at IDEAYA Biosciences, Cleave Biosciences, and Celgene Corporation. Mr. Smith has led numerous M&A, in-licensing and strategic equity investment transactions.

He spent his early career in equity research covering the biotechnology sector at RBC Capital Markets, Lazard Capital Markets, and Citi Research. Mr. Smith holds a B.S. in biology from the University of Texas at Arlington, an MBA in finance from Fordham University and an M.A. in biotechnology from Columbia University.

Robert Ticktin

General Counsel & Head of Operations

Prior to joining PMV Pharma, Mr. Ticktin was Associate General Counsel, Corporate, at Tesaro, Inc., a development and commercial oncology company (acquired by GSK), where he led corporate legal matters, including SEC reporting, business development and alliance management support. Prior to Tesaro, he was Senior Vice President and General Counsel at Epirus Biopharmaceuticals, a biosimilar company. Before his tenure at Epirus, Mr. Ticktin spent 10 years at Amgen Inc., where he held various leadership positions in the legal department. He began his legal career in New York City at global law firms, Simpson Thacher & Bartlett LLP and Latham & Watkins LLP. Mr. Ticktin received a B.A. in Economics from The Ohio State University and a J.D. from Fordham University School of Law.

Binh Vu, Ph.D.

Senior Vice President, Drug Discovery and CMC

Prior to joining PMV Pharma as Director of Research, Dr. Vu was a Research Leader at Roche Nutley where he spent 15 years working in small molecule oncology drug discovery. While at Roche, Dr. Vu was a key contributor to the discovery and development of Nutlins, small molecule MDM2 antagonists which target the p53 pathway. He has extensively published on p53 biology and drug discovery, and is an inventor on 14 issued US patents.

Dr. Vu received a Ph.D. in Chemistry from the University of California, Los Angeles, and completed an NIH Postdoctoral Fellowship at the University of Texas at Austin. He received a B.S. in Chemistry from the University of California, Irvine.

Laura De Leon

Vice President, Head of Clinical Operations

Laura joined PMV in February 2019 as Head of Clinical Operations with nearly two decades of clinical operations experience in the pharmaceutical industry. Laura has worked in multiple therapeutic areas in all phases of development across company type: large pharma, biotech, medical device, and CRO.

Throughout her career, Laura has held positions of increasing responsibility and leadership in clinical operations and program management at PAREXEL International, Thoratec Corporation, CombinatoRx, Inc., Takeda Oncology, Syndax Pharmaceuticals, EMD Serono, and Seres Therapeutics. Prior to joining PMV, Laura was the Director of Clinical Operations at Seres, responsible for the clinical operations strategy, team management, and oversight of study deliverables for two microbiome therapeutic assets in development including the lead product candidate SER-109 in Clostridioides difficile infection. Laura has extensive monitoring and global trial management experience and has been at the forefront of precision medicine in oncology since joining PMV.

Laura holds a BA in Psychology from Boston College and a MS in Health Product Regulation and Health Policy from Regis College.

Arshad Haque, M.D.

Vice President, Drug Safety and Pharmacovigilance

Dr. Haque is a General Medicine physician with over 17 years of pharmaceutical industry experience. He held leadership roles across various phases of drug development and drug safety-pharmacovigilance within both large and small pharmaceutical companies, such as Wyeth, Pfizer, Abbott, Alexion, Baxalta/Shire and Insmed. His work encompassed successful IND, NDA, BLA, global approvals and launch with postmarketing continuation of therapies in Oncology, Endocrine, Inflammatory, Infectious Diseases and various Rare diseases. Dr. Haque received his medical degree at Burdwan University in West Bengal, India, and went on to receive postgraduate training in internal medicine, pediatrics, cardiology, intensive coronary care, and anesthesiology. Prior to joining the pharmaceutical industry, he also earned a Master of Public Health from West Virginia University in Morgantown, West Virginia and served as a Surveillance Medical Officer working for the World Health Organization.

Masha Poyurovsky, Ph.D.

Vice President, Biology

Masha Poyurovsky, Ph.D., recently joined PMV as Vice President of Biology. Dr. Poyurovsky has more than a decade of experience leading novel platforms and a track record of advancing therapies from concept to clinic. Prior to joining PMV, she was employed at Kadmon (acquired by Sanofi in 2021), most recently as Vice President, Discovery Biology.

Dr. Poyurovsky obtained a doctorate in biochemistry from Columbia University and a bachelor of science in biochemistry and biophysics from the University of Pittsburgh. During her time as a Research Scientist and a Postdoctoral Research Fellow at Columbia University, Dr. Poyurovsky conducted studies on p53 and Mdm2. She is the author and co-author of numerous publications and patents in the area of cancer biology and drug discovery.

Crystal Zuckerman

Vice President, Human Resources

Prior to joining PMV Pharma, Crystal was Director of Talent Management for Bristol Myers Squib, formerly Celgene. While at Celgene, she supported various functions and C-Suite executives as an HR Business Partner. She played an integral role in the rollout of initiatives and managed partnerships with several corporate functions with more than 400 employees.

Combined, Crystal has over 20 years of Human Resources expertise in the areas of recruiting, talent management, training, and leadership development. She received her undergraduate degree from Rutgers University and her MA in Human Resources & Corporate Communications from Seton Hall.

Shibu Sleeba

Vice President, Information Technology

Shibu joined PMV in December 2020 as Head of IT. He has been in the pharmaceutical industry for over 16 years and is in tune with the sector’s compliance, quality, and security values. He has a broad range of business and technical expertise gained while working for Purdue Pharma, Acorda Therapeutics, and Minaris Regenerative Medicine. Each is in a different therapeutic area with unique manufacturing nuances. His people skills have supported his ascension into management roles and the creation of solid vendor relationships. Shibu has a Bachelor of Engineering in Telecommunication Engineering from B.M.S. College of Engineering, Bengaluru.